BACKGROUND: Isolated limb infusion (ILI) is a therapeutic option for patients with recurrent, unresectable extremity malignancies. METHODS: A prospectively collected single-institution database of patients undergoing ILI was analyzed for preoperative, intraoperative, and postoperative parameters and outcomes. RESULTS: From May 2007 to January 2012, a total of 76 patients successfully underwent initial ILI, and 28 after either previous hyperthermic isolated limb perfusion or ILI. Seventy-nine patients (74 %) had melanoma, 24 (22 %) sarcoma, 3 (3 %) Merkel cell, and 1 (1 %) squamous cell carcinoma. There were 55 (72 %) initial and 22 (79 %) repeat lower extremity (LE) ILIs, and 21 (78 %) initial and 6 (22 %) repeat upper extremity (UE) ILIs. Serologic toxicity, measured by serum creatine kinase (CK), peaked higher and later in LE ILIs, median 620 versus 124 IU/L, and postoperative day 4 versus 2, respectively (P < 0.05). LE ILIs had a longer hospital length of stay (LOS), median 6 versus 5 days (P < 0.0001). A median grade II Wieberdink regional toxicity was observed. Three-month follow-up was available in 94 (90 %). A response (overall response rate, ORR) was seen in 72 % of ILIs performed for melanoma and 58 % for sarcoma. No difference in response was observed between UE versus LE or between initial versus repeat ILIs. Repeat UE ILIs, however, appeared to have an improved ORR than repeat LE ILIs, 83 versus 64 %. CONCLUSIONS: ILI may be successfully performed for cutaneous and soft tissue malignancies. LE ILIs have higher CK levels and slightly longer LOS. Repeat ILIs are not associated with increased toxicity and similar ORR. UE ILIs may have better ORR.
BACKGROUND: Isolated limb infusion (ILI) is a therapeutic option for patients with recurrent, unresectable extremity malignancies. METHODS: A prospectively collected single-institution database of patients undergoing ILI was analyzed for preoperative, intraoperative, and postoperative parameters and outcomes. RESULTS: From May 2007 to January 2012, a total of 76 patients successfully underwent initial ILI, and 28 after either previous hyperthermic isolated limb perfusion or ILI. Seventy-nine patients (74 %) had melanoma, 24 (22 %) sarcoma, 3 (3 %) Merkel cell, and 1 (1 %) squamous cell carcinoma. There were 55 (72 %) initial and 22 (79 %) repeat lower extremity (LE) ILIs, and 21 (78 %) initial and 6 (22 %) repeat upper extremity (UE) ILIs. Serologic toxicity, measured by serum creatine kinase (CK), peaked higher and later in LE ILIs, median 620 versus 124 IU/L, and postoperative day 4 versus 2, respectively (P < 0.05). LE ILIs had a longer hospital length of stay (LOS), median 6 versus 5 days (P < 0.0001). A median grade II Wieberdink regional toxicity was observed. Three-month follow-up was available in 94 (90 %). A response (overall response rate, ORR) was seen in 72 % of ILIs performed for melanoma and 58 % for sarcoma. No difference in response was observed between UE versus LE or between initial versus repeat ILIs. Repeat UE ILIs, however, appeared to have an improved ORR than repeat LE ILIs, 83 versus 64 %. CONCLUSIONS: ILI may be successfully performed for cutaneous and soft tissue malignancies. LE ILIs have higher CK levels and slightly longer LOS. Repeat ILIs are not associated with increased toxicity and similar ORR. UE ILIs may have better ORR.
Authors: Theresa G Zogakis; Richard Essner; He-jing Wang; Leland J Foshag; Donald L Morton Journal: Ann Surg Oncol Date: 2007-03-01 Impact factor: 5.344
Authors: Mohamed A F Hegazy; Sherif Z Kotb; Hanem Sakr; Ebrahim El Dosoky; Talal Amer; Refaat A F Hegazi; Omar Farouk Journal: Ann Surg Oncol Date: 2006-11-09 Impact factor: 5.344
Authors: H Richard Alexander; Douglas L Fraker; David L Bartlett; Steven K Libutti; Seth M Steinberg; Perry Soriano; Tatiana Beresnev Journal: J Clin Oncol Date: 2009-11-09 Impact factor: 44.544
Authors: Georgia M Beasley; Rebecca P Petersen; Jin Yoo; Nicole McMahon; Thomas Aloia; William Petros; Gretchen Sanders; Tsung-Yen Cheng; Scott K Pruitt; Hilliard Seigler; Douglas S Tyler Journal: Ann Surg Oncol Date: 2008-06-05 Impact factor: 5.344
Authors: Georgia M Beasley; Abigail Caudle; Rebecca P Petersen; Nicole S McMahon; James Padussis; Paul J Mosca; Jonathan S Zager; Steven N Hochwald; Stephen R Grobmyer; Keith A Delman; Robert H Andtbacka; R Dirk Noyes; John M Kane; Hilliard Seigler; Scott K Pruitt; Merrick I Ross; Douglas S Tyler Journal: J Am Coll Surg Date: 2009-03-26 Impact factor: 6.113
Authors: Marc D Moncrieff; Hidde M Kroon; Peter C Kam; Paul D Stalley; Richard A Scolyer; John F Thompson Journal: Ann Surg Oncol Date: 2008-07-22 Impact factor: 5.344
Authors: Alfredo A Santillan; Keith A Delman; Georgia M Beasley; Paul J Mosca; Steven N Hochwald; Stephen R Grobmyer; Robert H Andtbacka; R Dirk Noyes; John M Kane; Merrick I Ross; Douglas S Tyler; Jonathan S Zager Journal: Ann Surg Oncol Date: 2009-06-19 Impact factor: 5.344
Authors: Jerry R Mendell; Louis G Chicoine; Samiah A Al-Zaidy; Zarife Sahenk; Kelly Lehman; Linda Lowes; Natalie Miller; Lindsay Alfano; Beverly Galliers; Sarah Lewis; Darren Murrey; Ellyn Peterson; Danielle A Griffin; Kathleen Church; Sharon Cheatham; John Cheatham; Mark J Hogan; Louise R Rodino-Klapac Journal: Hum Gene Ther Date: 2019-04-19 Impact factor: 5.695
Authors: F C Wright; S Kellett; N J Look Hong; A Y Sun; T P Hanna; C Nessim; C A Giacomantonio; C F Temple-Oberle; X Song; T M Petrella Journal: Curr Oncol Date: 2020-06-01 Impact factor: 3.677
Authors: Diego J Muilenburg; Georgia M Beasley; Zachary J Thompson; Ji-Hyun Lee; Douglas S Tyler; Jonathan S Zager Journal: Ann Surg Oncol Date: 2014-09-06 Impact factor: 5.344
Authors: Tavis A Read; Aaron Smith; Janine Thomas; Michael David; Matthew Foote; Michael Wagels; Andrew Barbour; B Mark Smithers Journal: J Surg Oncol Date: 2018-03-12 Impact factor: 3.454